---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-117318"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2024-10-25T23:59:59+00:00"
generated_at: "2026-05-30T10:07:17.794396+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine presents positive Phase 1b data for DISC-0974 in CKD anemia at ASN Kidney Week

## Summary
- Dose-dependent hepcidin reduction >75% from baseline at highest dose (60 mg); transferrin saturation up to 3x baseline.
- Mean hemoglobin increase of +0.55 g/dL at 60 mg vs +0.21 g/dL placebo; individual max increase +1.8 g/dL.
- All treatment-related adverse events Grade 1 or 2; majority unrelated to DISC-0974; acceptable safety profile.
- Data from SAD cohorts (28, 40, 60 mg) in Stage 2-5 NDD-CKD anemia; dose escalation and multiple-dose portion ongoing.

## SEC filing metadata
- accession: 0000950170-24-117318
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2024-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000095017024117318/0000950170-24-117318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000095017024117318/iron-20241025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-117318
- JSON: https://secwatch.observer/filing/0000950170-24-117318.json
- Plain text: https://secwatch.observer/filing/0000950170-24-117318.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.